Otsuka buys Transcend in $1.2B deal, nabbing MDMA analog for psychiatric conditions
Otsuka buys Transcend in $1.2B deal, nabbing MDMA analog for psychiatric conditions
Otsuka buys Transcend in $1.2B deal, nabbing MDMA analog for psychiatric conditions
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.